47 results about "Cellular lipid" patented technology

The present invention relates to a use of benzethonium chloride in preparing a drug for improving or treating non-alcoholic fatty liver disease, and relates to the technical field of new uses of products. The present invention discovers for the first time a new use of benzethonium chloride for improving or treating non-alcoholic fatty liver disease. Benzethonium chloride can reduce hepatocyte lipid deposition and regulate hepatocyte lipid metabolism disorder by intervening in a cell lipid deposition model; it can improve liver lipid accumulation in mice caused by lipid metabolism disorder by administering through the digestive tract, and can improve liver coefficient, liver function, hepatic lobular inflammation, and liver fibrosis. The benzethonium chloride of the present invention can be used for the preparation of drugs for improving or treating non-alcoholic fatty liver disease. The benzethonium chloride of the present invention can inhibit the expression of human apolipoprotein C3, thereby reducing the generation of lipids, and is applied to drugs for treating non-alcoholic fatty liver disease, opening up a new use of benzethonium chloride and providing a new drug option for treating non-alcoholic fatty liver disease.

The utility model discloses a cell lipidomics detection sampling device which comprises a test tube assembly, a cell lipidomics detection sampling device and a cell lipidomics detection sampling device, the suction tube assembly comprises a suction tube main body, a glass rod, a piston and a holding rod; the middle of the test tube body is movably connected with the straw body, the middle of the straw body is movably connected with the glass rod, the piston is fixedly mounted at the bottom of the glass rod, and the holding rod is fixedly mounted at the top of the glass rod; the device further comprises a fixed density assembly. The fixed density assembly comprises a threaded cylinder and a screw column; the top of the test tube main body is fixedly provided with a threaded cylinder, and the outer ring of the test tube main body is fixedly provided with a screw column which is connected with the threaded cylinder. The utility model relates to a cell lipidosome sampling device, which solves the problem that cell lipidosome liquid in a test tube is easy to contact with the outside and the cell lipidosome is easy to pollute because a rubber head dropper is directly inserted into a test tube for sampling in the existing cell lipidosome and a gap is reserved between the rubber head dropper and the test tube in the process.

This invention belongs to the field of biomedical technology, specifically relating to a compound extracted from *Acer buergerianum* (a type of shrub), its extraction method, and its application in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease. This invention is the first to obtain a natural compound with a novel structure from *Acer buergerianum*, and provides a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity and no significant cytotoxicity to normal cells. It can inhibit the expression of fatty acid synthases ACC, ACLY, and FAS, thereby inhibiting de novo fatty acid synthesis in cells, suppressing lipid droplet accumulation, and reducing cellular lipid levels. This compound has broad application prospects in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease.

The invention relates to a full-automatic high-flux high-coverage single-cell lipidomics analysis device and method, and the device comprises a valve which is provided with a quantitative groove; the cell suspension injection assembly is communicated with the sample inlet of the quantitative tank through a capillary tube; the capillary chromatographic column spray needle comprises a body and a tip end, the body is communicated with the chromatographic column connector of the quantitative groove, the tip end is aligned with a sample injection conical opening of the mass spectrometer, the capillary chromatographic column spray needle is filled with filler, the capillary chromatographic column spray needle is sleeved with a metal tube, and the metal tube is connected with the capillary chromatographic column spray needle. An electric field is applied to the metal tube in time; the supercritical fluid injection part is communicated with the mobile phase inlet of the quantitative tank and is used for injecting supercritical fluid into the quantitative tank, so that a single cell sample is extracted on line. In a single experiment, the device can quickly obtain the number of analysis samples with statistical significance.

The invention discloses a single-cell lipid online extraction and chromatographic separation mass spectrometry device and method based on supercritical fluid. The device comprises a supercritical fluid pump, a six-way valve, a quantitative loop and a capillary chromatographic column spray needle, the capillary chromatographic column spray needle comprises a body and a tip end, the tip end is arranged to be aligned with a sample inlet of the mass spectrometer when the capillary chromatographic column spray needle supplies samples to the mass spectrometer, one port of the six-way valve is connected with the other end of the capillary chromatographic column spray needle, and the other port of the six-way valve is connected with the supercritical fluid pump; a filter with the aperture of 2.0-5.0 microns is arranged at the tail end of a quantitative ring matched with the six-way valve; and the tip of the capillary chromatographic column spray needle is filled with a chromatographic filler. The device is simple in structure and easy to operate, the chromatographic filler and the capillary tube are easy to purchase, and the cost is low; the device does not need complex pretreatment, is convenient to use and wide in application range, and can be used as an effective means for cancer diagnosis and treatment, drug screening, systematic biology, cell heterogeneity research and the like.

The invention relates to the technical field of cell transfection experiment methods, and aims at effectively solving the cell liposome transfection tolerance phenomenon by increasing circulating cell hydrostatic pressure treatment in a cell liposome transfection experiment to improve the liposome transfection efficiency. In a cell liposome transfection experiment, the liposome transfection efficiency is improved by adding cell hydrostatic pressure treatment of a circulating mode; the circulation mode is that the hydrostatic pressure of the cells is maintained to be periodically changed in a set pressure interval value under a set frequency. The cell lipidosome transfection tolerance phenomenon is improved, and especially the transfection efficiency of lipidosome transfection tolerance cells such as primary culture cells and suspension culture cells is improved.

To provide a method and an arrangement for screening a membrane protein.SOLUTION: An arrangement includes: a first fused protein containing a membrane protein fused to one member of a binding pair, and existing in a boundary layer such as a wall of a cell, a liposome or a vesicle; and a second fused protein containing an intracellular ligand of the membrane protein fused to the other member of the binding pair. The binding pair can generate a detectable signal.SELECTED DRAWING: None

The present invention relates to the field of fluorescent probe technology, and specifically to the use of a polarity-sensitive fluorescent probe in the preparation of a non-alcoholic fatty liver disease detection reagent. The chemical name of the polarity-sensitive fluorescent probe is 6-(dimethylamino)-2-naphthaldehyde; the non-alcoholic fatty liver disease detection reagent has the following functions: (1) imaging of lipid droplets in living cells; (2) qualitative and quantitative detection of cell lipid droplet polarity; (3) distinguishing between normal cells and cancer cells; (4) dynamically monitoring the lipid droplet formation process; (5) distinguishing and detecting different degrees of non-alcoholic fatty liver tissue. The present invention provides a very promising tool for studying the polarity of lipid droplets of different types of cells and distinguishing and detecting different degrees of non-alcoholic fatty liver tissue, which is helpful for timely diagnosis of early non-alcoholic fatty liver disease.

The invention discloses application of GW7647 in preparation of a medicine for inhibiting cell lipid peroxidation caused by African swine fever virus protein, and belongs to the technical field of medicine. The invention proves the application of GW7647 in preparation of drugs for inhibiting cell lipid peroxidation caused by African swine fever virus protein; the African swine fever virus protein is African swine fever virus A151R. Experiments prove that ASFV A151R can promote cell lipid peroxidation damage and induce cell lipid peroxidation; the GW7647 can inhibit cell lipid peroxidation caused by ASFV A151R, and can be applied to research on lipid peroxidation of the African swine fever virus on cells; the medicine for inhibiting cell lipid peroxidation has important value for researching the anti-infection capability of an African swine fever virus infected host, the relationship between cell lipid peroxidation and innate immunity and the like.

The invention discloses an extraction method and application of a dermal fat cell lipid component. The extraction method comprises the following steps: (1) extracting primary dermal fibroblasts from a 0th-day mouse; (2) carrying out planking culture on the primary dermal fibroblasts by using a DMEM + + + culture medium until the cell adherence density reaches 100%, then carrying out in-vitro adipogenic differentiation induction culture by using an adipogenic differentiation culture medium, then carrying out maintenance culture by using a maintenance culture medium until the cells are in an early fat state, and separating to obtain supernate of early differentiation culture cells; and (3) extracting and separating the supernate obtained in the step (2) by using a Matyash method to obtain the dermal fat cell lipid component. According to the method, lipid and protein components in the early differentiated fat cell culture supernatant are extracted and separated, and the obtained lipid component has a remarkable immune regulation function and can remarkably inhibit the inflammatory state of macrophages and proliferation of keratinocytes.

The present invention relates to the field of natural medicine and pharmaceutical technology, and discloses a new compound, novofuran, prepared from Nocardia spp., as well as its preparation method and application. The present invention isolated Nocardia spp. ZHD001 for the first time from sediments collected from the sea area surrounding Zhoushan, and further isolated and studied the fermentation product of Nocardia spp. ZHD001 to obtain novofuran. The present invention determined the chemical structure of the new compound novofuran by analyzing high-resolution mass spectrometry (HRESIMS), hydrogen spectrum, carbon spectrum, HMQC spectrum, HMBC spectrum, and COSY spectrum data of novofuran. A series of studies have shown that novofuran can significantly reduce lipid accumulation in a HepG2 cell lipid model, exhibits lipid-lowering biological activity, and can be used to prepare lipid-lowering drugs or lipid-lowering health foods, showing excellent development and application prospects.

The invention discloses a transmembrane protein 16F and application of a gene coded by the transmembrane protein 16F as a target spot in preparation of a medicine for regulating and controlling tumor ferroptosis. The tumor is any one of lymphoma, melanoma, colon cancer, cervical cancer, fibrosarcoma and ovarian epithelial cancer. The invention finds that TMEM16F is a ferroptosis inhibiting factor which does not change a cell lipid peroxidation process, and shows that the spatial distribution of oxPLs can regulate ferroptosis. In the ferroptosis process, the TMEM16F-mediated phospholipid overturning process is activated, and the effect of regulating and controlling phospholipid redistribution is achieved. In addition, the combination of TMEM16F defect and anti-PD-1 treatment shows a synergistic anti-tumor effect, and initiates a strong tumor immunological rejection reaction. The ivermectin has the biological activity of inhibiting the overturning function of TMEM16F phospholipid, and the inhibition effect of the ivermectin on TMEM16F effectively enhances the reactivity of anti-PD-1 treatment.

The present invention discloses a tuna swim bladder hypolipidemic and antioxidant oligopeptide and its application. The present invention uses tuna swim bladder as a raw material, and after enzymatic hydrolysis, ultrafiltration, gel chromatography purification, and RP-HPLC purification, the tuna swim bladder hypolipidemic and antioxidant oligopeptide His-Ser-Gly-Pro-Tyr-Met (HSGPYM) is prepared, and its molecular weight is 690.8 Da. The HSGPYM of the present invention can significantly reduce the contents of triglyceride (TG) and total cholesterol (TC) in the lipid accumulation model of HepG2 cells, showing good lipid-lowering activity; at the same time, it can significantly increase the antioxidant enzyme level in the cell model, effectively scavenge excessive reactive oxygen species, and reduce oxidative stress damage. The HSGPYM of the present invention has the advantages of being safe, non-toxic, and having strong lipid-lowering and antioxidant capabilities, and can be used for the development of functional products for the treatment of non-alcoholic fatty liver disease, and can also be used as an additive for health products and foods.

The invention discloses an application of N-trans-feruloyltyramine in treatment of a non-alcoholic fatty liver disease. The invention further discloses a verification method for proving that the N-trans-feruloyltyramine is used for treating the non-alcoholic fatty liver disease. The invention further discloses a medicine for treating the non-alcoholic fatty liver disease. The invention discloses N-trans-feruloyl tyramine which can be applied to prevention or treatment of NAFLD (non-alcoholic fatty liver disease). In-vitro cell experiments find that N-trans-feruloyltyramine can reduce lipid deposition and oxidative stress damage of HepG2 cells induced by OA / PA, reduce the level of TC and TG in the cells by promoting efflux of TC and TG in the cells, reduce expression of MDA in the cells and promote expression of SOD, CAT and GSH in the cells; in-vivo animal experiments show that the N-trans-feruloyltyramine can reduce the levels of TC, TG and LDL-C in serum, reduce the levels of TC, TG, LPO, ALT and AST in liver, and relieve infiltration of inflammatory cells in liver tissue.

The present disclosure provides lipid nanoparticles that are particularly beneficial in inducing an immune response in a subject, particularly by stimulating CD8+ T cells associated with protein or protein fragments of interest. The lipid nanoparticles can have a negative zeta potential and / or particular configurations and / or relative amounts of a phospholipid, an ionizable lipid, and a conjugated lipid. The disclosure also provides vaccines, other pharmaceutical compositions, and methods including the provided lipid nanoparticles.

This invention relates to a compound extracted from *Dryopteris macrocarpa*, its extraction method, and its application in the preparation of drugs for the prevention and / or treatment of non-alcoholic fatty liver disease. This invention provides a novel natural compound obtained from *Dryopteris macrocarpa* for the first time, along with a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity to normal cells. It can inhibit fatty acid uptake in cells by suppressing the expression of fatty acid uptake-related genes FATP2 and CD36, thereby inhibiting lipid droplet accumulation and reducing cellular lipid levels. This compound can be applied in the preparation of drugs for the prevention and / or treatment of non-alcoholic fatty liver disease.

This invention discloses refined mulberry seed oil, its extraction method, and its application. Compared with the prior art, the advantages are: (1) The method of this invention uses agricultural waste (mulberry seeds) as raw material, and obtains mulberry seed oil through low-moisture enzymatic hydrolysis pretreatment combined with high-temperature pressing. The enzyme dosage is low (0.1%~1.0%), ethanol is recycled, solvent loss is small, the process is simple, the operation is convenient, and it is easy to realize industrial-scale production; (2) The mulberry seed oil prepared by this invention has an unsaturated fatty acid content of up to 88.26%, of which the linoleic acid content is 81.6%; (3) The mulberry seed oil of this invention shows significant lipid-regulating activity in both cell and nematode models: it can improve the lipid content index and protein expression of hyperlipidemic cells, and it can also regulate nematode-related genes and reduce lipid accumulation; (4) This invention uses mulberry seeds, a waste of silkworms, as raw material, and realizes the high-value utilization of agricultural by-products, which has good industrial application prospects and economic and social benefits.

According to the present invention, the research results show that the influence of Procyanidin C1 and Procyanidin C2 on inhibition of oleic acid (OA)-induced HepG2 cell lipid accumulation and oxidative stress is provided; on the basis, the invention provides the application of the procyanidin C1 or / and the procyanidin C2 in preparation of the medicine for preventing or treating the non-alcoholic fatty liver disease, and the application of the procyanidin C1 or / and the procyanidin C2 in preparation of the medicine for preventing or treating the non-alcoholic fatty liver disease.

The invention provides a preparation method of molecularly imprinted hydrogel specifically bound with sialic acid, and relates to the technical fields of organic chemistry, pharmaceutics, molecular biology and the like. The synthesis method of the molecularly imprinted hydrogel specifically bound with sialic acid comprises the following steps: 1) synthesizing the molecularly imprinted hydrogel taking sialic acid as a target spot; (2) eluting and purifying the molecularly imprinted hydrogel; 3) verifying and characterizing the molecularly imprinted polymer; (4) verifying the in-vitro adsorption of the molecular imprinting hydrogel to the sialic acid; 5) biological function verification of the molecularly imprinted hydrogel; and 6) verifying the molecularly imprinted hydrogel as a drug loading system. The molecularly imprinted hydrogel specifically bound with sialic acid is obtained, the sialic acid is specifically bound and removed, liver cell lipid accumulation is effectively reduced, and the molecularly imprinted hydrogel has profound significance in the field of treatment of metabolic diseases such as non-alcoholic fatty liver disease.

The present invention provides a polypeptide for inhibiting fat accumulation and its use. Its amino acid sequence is MNGLTLGSIPKEEAEKERQGWLEAAK. This polypeptide can inhibit CD36 transport of extracellular fatty acids, reducing cellular lipid uptake and accumulation, and effectively inhibiting the accumulation of intracellular triglycerides and other fats caused by free fatty acids.

The application discloses a gastrodin-EGCG composition and application thereof in treating and improving lipid metabolism disorder, wherein the composition takes gastrodin and epigallocatechin gallate as main active ingredients, and the gastrodin and the epigallocatechin gallate are combined in a certain proportion. In a HepG2 cell lipid deposition model induced by mixed fatty acids, the gastrodin-EGCG composition can reduce intracellular lipid droplet deposition and triglyceride content, and the improvement effect thereof is better than that of the gastrodin or the EGCG alone, and the composition has a significant synergistic effect. The composition can be used for preparing a medicine or a health food for improving liver cell lipid deposition, regulating lipid metabolism disorder or assisting in improving abnormal states related to lipid accumulation.

The present application relates to the technical field of compounds, in particular to a natural active compound pseudo-norfurane, a preparation method and application thereof. The present application provides a natural active compound pseudo-norfurane, which has the structure shown in the following formula (I), the compound formula (I) of the present application can significantly reduce the lipid accumulation in a HepG2 cell lipid model, has a hypolipidemic biological activity, can be used for preparing a hypolipidemic drug or a hypolipidemic health food, and has a good development and application prospect.

The invention discloses a construction method of a hepatocyte lipid accumulation model and application of the hepatocyte lipid accumulation model in screening of lipid-lowering functional substances, and belongs to the technical field of detection. The method comprises the following steps: culturing AML12 cells by using a DMEM / F-12 culture medium containing 10% of FBS, 1 * ITS and 1% of P / S, carrying out combined intervention for 24-72 hours by using 2%-3% of ethanol and 50-100 [mu] M of palmitic acid for molding, and quantifying the intracellular lipid accumulation degree through BODIPY fluorescence detection. The model simulates pathological mechanisms of alcoholism and high fat diet, AML12 cells retain key enzymes of alcohol metabolism, the cell viability is maintained at 60%-80% after modeling, and the lipid fluorescence intensity is remarkably improved compared with that of a blank group. The model can efficiently screen lipid-lowering and liver-protecting functional substances for relieving alcoholic fatty liver, is sensitive and quantifiable in detection, and provides a reliable tool for screening related medicines and extracts.

Polynucleotides such as DNA are stored inside vesicles formed from self-assembling membranes. The vesicles may be protocells, liposomes, micelles, colloidosomes, proteinosomes, or coacervates. The vesicles may include surface functionalization to improve polynucleotide encapsulation and / or to bind polynucleotides having specific sequences. Encapsulation in vesicles provides protection for the polynucleotides. Additional protection is provided by addition of one or more stabilizers. The stabilizer may be nucleic-acid stabilizers that stabilize the polynucleotides or may be a protective structural layer around the vesicles such as a layer of silica. A process for stably storing polynucleotides in vesicles and a process for recovering stored polynucleotides from vesicles are both disclosed. The polynucleotides may be used for storage of digital information.

The application discloses the use of ACY-1 modulators as a therapeutic target for fatty liver disease and drug screening. By constructing a HepG2 cell lipid deposition model, it is found for the first time that ACY1 overexpression can exacerbate cell triglyceride accumulation; by constructing a MASH mouse model induced by a high-fat high-cholesterol high-fructose diet, it is found that ACY1 overexpression can exacerbate MASH progression; based on these findings, a drug screening method for preventing or treating fatty liver disease is constructed, and 2-hydroxyhexanoic acid (2-HHA) is screened out, which can significantly inhibit the in vitro enzyme activity of ACY1, and can alleviate abnormal cell triglyceride accumulation caused by palmitic acid-oleic acid stimulation at the cell and animal levels, and significantly improve the weight gain, liver lipid deposition, fatty degeneration, inflammatory infiltration and fibrosis of MASH mice induced by a high-fat high-cholesterol high-fructose diet, and the like, in addition, the inhibitor 2-hydroxyhexanoic acid can significantly reduce the abnormally increased serum ALT, AST and liver TC and TG of MASH mice.

A super-bright fluorescent probe for cellular lipid droplets and its application in the preparation of bioimaging reagents, belonging to the field of bioimaging technology. Aiming at the deficiencies of the existing fluorescent imaging probes for cellular lipid droplets in terms of insufficient photostability and insufficient selectivity for lipid droplet staining, the present invention selects a fluorescent molecule based on stilbene derivatives in the development of a new type of fluorescent probe for lipid droplet imaging. While exhibiting high photostability, this fluorescent molecule has excellent selectivity for lipid droplet staining. This fluorescent probe can be used to prepare reagents for specifically labeling lipid droplets in cells, visually tracking the dynamic trajectories of cellular lipid droplets, and quantitatively measuring the movement speed of cellular lipid droplets. The fluorescent probe Lipi-Bright described in the present invention has excellent photostability and staining selectivity. Under the same staining and imaging conditions, Lipi-Bright exhibits more excellent photostability and staining selectivity than commercial fluorescent probes for lipid droplets, and has great application prospects.

The invention discloses a type I 5 alpha-reductase inhibitory peptide as well as a composition and application thereof, and the type I 5 alpha-reductase inhibitory peptide can be used for remarkably inhibiting expression increase of a type I 5 alpha-reductase gene, abnormal expression of a lipid synthesis related gene and abnormal expression of an inflammatory factor gene caused by androgen and remarkably inhibiting lipid generation of cells. The compound can be used for preparing medicines, cosmetics, skin care products, food or health care products, can be used as an oil-control component or an anti-acne component, and has a wide application prospect.

The application discloses a traditional Chinese medicine polysaccharide with lipid-lowering activity and a preparation method and application thereof, relates to the technical field of biological medicine, and the traditional Chinese medicine polysaccharide is neutral uniform polysaccharide ACP1 in allium chinense, the weight-average molecular weight is 17.96 kDa, the polydispersity index is 1.726, is composed of glucose and fructose, and the molar ratio is 2.53%:97.47%. The neutral uniform polysaccharide in allium chinense provided in the application is a new neutral uniform polysaccharide ACP1 extracted from allium chinense, can effectively improve the lipid deposition of AML-12 cells induced by oleic acid, has significant lipid-lowering activity, and is high in safety. The preparation method of the neutral uniform polysaccharide in allium chinense provided in the application is good in repeatability, the obtained neutral uniform polysaccharide is high in purity, and is beneficial to industrial production.

The invention provides a method and a device for screening membrane proteins. The device comprises a first fusion protein comprising a membrane protein present in a boundary layer (e.g., the wall of a cell, liposome, or vesicle) and fused to one member of a binding pair, and a second fusion protein comprising an intracellular ligand fused to the membrane protein of the other member of the binding pair, wherein the combination pair is capable of generating a detectable signal.

This disclosure provides methods of increasing in vivo transfection efficiency and pharmacologic activity of T cells, by administering multiple small doses within a compact time period of T cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor that recognizes an antigen of a cell against which immune activity is to be directed. Also provided are methods of depleting B cells, and methods of treating B cell-mediated diseases and disorders by depleting B cells and achieving immunological reset, entailing administration of immune cell-targeted lipid nanoparticles encapsulating mRNA encoding an antigen receptor recognizing a B cell marker as multiple small doses within a compact time period. The antigen receptor can be a T cell receptor or a chimeric antigen receptor.